Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.67 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | GAA | P10253 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 4/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861100 | 0.87 | PTPN1 (0.61) | PTPN1MAPTGAAALDH1A1KDM4E | |
| SCHEMBL29954829 | 0.87 | PTPN1 (0.61) | PTPN1MAPTGAAALDH1A1KDM4E | |
| SCHEMBL11234460 | 0.83 | PTPN1 (0.68) | PTPN1MAPTGAAALDH1A1KDM4E | |
| SCHEMBL911098 | 0.80 | ALDH1A1 (0.68) | PTPN1MAPTGAAALDH1A1PTPN2 | |
| SCHEMBL5363245 | 0.80 | PTPN1 (1.00) | PTPN1ALDH1A1PTPN2MAOBMAOA | |
| SCHEMBL13978663 | 0.80 | PTPN1 (1.00) | PTPN1KDM4EPTPN2MAOBMAOA | |
| SCHEMBL12174817 | 0.80 | PTPN1 (0.67) | PTPN1MAPTGAAALDH1A1KDM4E | |
| SCHEMBL29951299 | 0.80 | PTPN1 (1.00) | PTPN1KDM4EPTPN2MAOBMAOA | |
| SCHEMBL29952420 | 0.80 | ALDH1A1 (0.68) | PTPN1MAPTGAAALDH1A1PTPN2 | |
| SCHEMBL177572 | 0.80 | PTPN1 (1.00) | PTPN1MAPTGAAALDH1A1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930565-A | Hydroxy flavonoid derivative and preparation method and application thereof | 重庆文理学院 | 2025-05-06 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-11078159-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078159-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | HGF, SMAD3, HRAS | PTPN1 3234/4885MAPT 4072/4885GAA 3140/4885 |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | HGF, SMAD3, HRAS | PTPN1 3234/4885MAPT 4072/4885GAA 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.